Cohance Lifesciences per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹2.78₹4.69₹10.52₹11.80₹16.16
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹2.74₹4.68₹10.45₹11.80₹16.16
₹102.23₹102.23₹66.64₹80.56₹68.16
₹55.97₹59.29₹47.04₹41.30₹52.65
—₹9.63₹11.32₹14.08₹17.71
₹3.88₹3.88₹5.20₹12.05₹6.49
—₹0.00₹0.00₹0.00₹8.00
38.338.325.525.525.5
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

COHANCE₹452.00

Cohance Lifesciences Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABSYNGENEASTERDMLALPATHLABNATCOPHARMWOCKPHARMANEULANDLABNHMcap ₹17,294 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS16.1611.8010.524.692.78
Diluted EPS16.1611.8010.454.682.74
Book Value per Share68.1680.5666.64102.23102.23
Revenue per Share52.6541.3047.0459.2955.97
Cash Flow per Share17.7114.0811.329.63—
Free Cash Flow per Share6.4912.055.203.883.88
Dividends per Share8.000.000.000.00—
Shares Outstanding (cr)25.525.525.538.338.3
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.